ERBB2 and hepatocellular carcinoma: To examine the combinatory effect of H2-18 and GDC-0941 on ErbB2 signaling, the trastuzumab-sensitive cell line BT-474 and the trastuzumab-resistant cell line HCC-1954 were treated with indicated treatments and then cell lysates were subjected to western blot.